City

Liverpool (1)

New York (1)

Seoul (1)

Condition

Oropharynx (4)

Hypopharynx (2)

Larynx (2)

Hemorrhage (1)

Hemostatics (1)

Oral Cavity (1)

Pain (1)

Squamous Cell Carcinoma of the Oral Cavity (1)

Stage II-IVB Operable HNSCC Oral Cavity (1)

Overall Status

Completed (2)

Not yet recruiting (1)

Recruiting (1)

Sign in for free

Phase

n/a (2)

phase 2 (1)

Sponsor

Brooke Army Medical Center (1)

Icahn School of Medicine at Mount Sinai (1)

University of Liverpool (1)

Yonsei University (1)

Collaborator

William Marsh Rice University (1)

Intervention

durvalumab (1)

durvalumab + tremelimumab (1)

grape flavored puritan junior tongue depressor (1)

purabond (1)

traditional unflavored puritan regular tongue depressor (1)

Study Documents

Intervention Type

device (1)

drug (1)

other (1)

Funder Type

Other (3)

U.S. Fed (1)

Study Type

Interventional (3)

Observational (1)

oropharynx

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Pain, Hemorrhage, Hemostatics Trial in Liverpool (PuraBond)

Not yet recruiting

Pain
+4 more

PuraBond

Liverpool, United Kingdom

Liverpool University Hospitals Foundation Trust (LUHFT)

Mar 15, 2023

Stage II-IVB Operable HNSCC Oral Cavity, Hypopharynx, Oropharynx Trial in Seoul (Durvalumab, durvalumab + tremelimumab)

Recruiting

Stage II-IVB Operable HNSCC Oral Cavity
+3 more

Durvalumab
durvalumab + tremelimumab

Seoul, Korea, Republic of

Yonsei University Health System, Severance Hospital

Apr 22, 2021

Oropharynx Trial (Grape flavored Puritan Junior tongue depressor, Traditional unflavored Puritan Regular Tongue Depressor)

Completed

Oropharynx

Grape flavored Puritan Junior tongue depressor
Traditional unflavored Puritan Regular Tongue Depressor

(no location specified)

Mar 23, 2017

Ex Vivo Multimodal Imaging of Upper Aerodigestive Epithelium

Completed

Squamous Cell Carcinoma of the Oral Cavity
+3 more

New York, New York

Mount Sinai School of Medicine

Jun 20, 2012